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ABSTRACT
The decision for surgery in the management of asymptomatic severe degenerative mitral regurgitation (MR) is about doing the
right thing at the right time and place. European and American guidelines have provided us with guidance on surgical
indications, albeit with different levels of recommendations. However, the timing for surgery especially in asymptomatic patients
not meeting Class I indications for intervention, i.e. no evidence of left ventricular dysfunction is still avidly debated. In this review,
we will present the literature on the indications and timing of surgical intervention in asymptomatic severe MR, covering
guidelines from both societies. We will also touch on the emerging role of other imaging techniques, biomarkers and exercise
stress testing. Finally, we will present arguments for and against both management strategies, i.e. early surgery and watchful
waiting. To summarize, the management of patients with asymptomatic severe degenerative MR should be a joint decision
between all members of the Heart Team and tailored according to the availability of surgical expertise, patient’s surgical risk and
patient’s wishes.
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Introduction
Degenerative mitral valve (MV) disease is the most com-
mon cause of mitral regurgitation (MR) in the developed
world.1 Often, patients with degenerative MR are asymp-
tomatic, even if the regurgitation is severe. Studies on the
natural history of severe MR have shown that even in
patients without symptom, some may develop downstream
hemodynamic consequences over time.2–4 These conse-
quences often portent poor prognosis and surgery is indi-
cated when they emerge. Thus, the key to the management
of severe MR in asymptomatic patients is to identify these
adverse hemodynamic consequences early with the hope
that timely surgical intervention may reverse them before
they become irreversible. With the improvement of surgi-
cal outcomes, surgery has cemented its status in the man-
agement of severe MR to be superior to medical therapy
when a patient becomes symptomatic or develops down-
stream complications of severe MR. In this regard, there is
little question about whether to carry out surgery or not
when surgical expertise is available and the patient is a
candidate for surgery. In recent years, the debate on the
management of severe MR has been evolving around
asymptomatic patients who have yet to meet Class I sur-
gical criteria for MV surgery: should we advocate prophy-
lactic surgery before complications of MR set in, i.e. early
surgery?; or should we wait and watch the patient closely,
seeking surgical attention at the very onset of
complication, i.e. watchful waiting? The 2017 ACC/AHA
guidelines for the management of valvular heart disease
provide a Class IIa recommendation for surgery in asymp-
tomatic patients with chronic severe primary MR and
preserved left ventricular (LV) function if the expected
operative mortality rate is <1% and the probability of a
successful and durable repair is >95%.5 This however, did
not end the early surgery versus watchful waiting debate.
In fact, the debate is still going strong and far from over,
as we will reveal subsequently.
The present review will (1) cover the indications for sur-
gery and evidence behind the guidelines; (2) touch on emer-
ging imaging techniques and biomarkers that contribute to
the risk stratification of MR; (3) discuss the debate on early
surgery versus watchful waiting strategy.
Discussion
Triggers for surgery in asymptomatic patients
In asymptomatic patients, surgery should be considered if
there is evidence of adverse downstream consequences of
severe MR. There is, however, a lack of randomized con-
trolled trials in the literature; thus, the highest evidence
available is of Level B. The triggers for surgery include
impaired LV function, increased systolic pulmonary artery
pressure (sPAP), or development of atrial fibrillation (AF)
(Table 1).
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LV function and size
LV ejection fraction
The LV dimensions and ejection fraction reflect the heart’s
ability to adapt to increased volume load. In the chronic com-
pensated phase (the patient could be asymptomatic), the forward
stroke volume is maintained through an increase in LV ejection
fraction (EF) explained by the Frank–Starlingmechanism. In the
chronic decompensated phase (the patient could still be asymp-
tomatic or may fail to recognize deterioration in clinical status),
the forward stroke volume decreases and the left atrial (LA)
pressure increases significantly (Figure 1). The LV contractility
can thus decrease silently and irreversibly. However, the LVEF
may still be in the low normal range despite the presence of
significant muscle dysfunction. Not uncommonly the LVEF
decreases after surgery. This is intuitive and at the same time,
substantiated by evidence. Patients with a preoperative LVEF
>60% have been shown to have better long-term post-operative
survival compared to the EF 50–60% and EF <50% groups.6 This
finding is in concordance with the Mitral Regurgitation
International Database (MIDA) registry, which showed that
LVEF ≤60% was associated with higher all-cause mortality.7 Of
note, the lack of contractile reserve during exercise echocardio-
graphy (< 4% increase in EF) also predicts decrease in LVEF and
symptoms at follow-up in medically managed patients; it also
predicts post-operative LV systolic dysfunction in surgically
treated patients.8,9 In the current guidelines, surgery is recom-
mended (class I) in asymptomatic patients with severe degen-
erative MR when the LV ejection is ≤60%. No recommendation
is specifically made in case of no contractile reserve.
LV end-systolic diameter
The end-systolic diameter (ESD) is determined by LV contrac-
tility, afterload and the degree of eccentric LV remodeling, but
not by preload. It could, in some cases, be more appropriate to
monitor global LV function. An ESD ≥ 45mm (ESC/EACTA) or
>40 mm or > 22 mm/m2 (AHA/ACC) also indicates (class I) the
need for mitral valve surgery in asymptomatic patients with
severe degenerative MR. Both cut-offs predict post-operative
LV dysfunction, though the 40 mm threshold has been only
highlighted in patients with flail MV in the MIDA registry.10,11
The most important caveat of LVESD is that it is a unidimen-
sional measurement of LV size. When LV remodels as a con-
sequence of severe MR, it often assumes a spherical shape, with
enlargement of mid to apical cavity. This would have been
missed if LVESD were used as the sole representation of LV
dimension. LV end-systolic volume obtained either from 3D
echocardiography or cardiac magnetic resonance imaging
(MRI) can better estimate the extent of LV remodeling.12,13
LV ejection index
The LV ejection index is an indexed product of LVESD/LV
outflow tract velocity time integral. It reflects changes in LV
cavity as a result of remodeling and LV systolic function. In
severe MR, the LVESD increases as a result of volume overload,
while the LV outflow tract velocity time integral decreases,
following the decrease in LV contractility. Together, these
changes give rise to a markedly increased LV ejection index.
A LV ejection index >1.13 is associated with post-operative LV
dysfunction and mortality, even in patients with a pre-operative
LVEF >60%.14 Although not included in the guidelines as part
of the surgical criteria, it is nevertheless a handy parameter that
takes into account both the size and function of the LV.
Pulmonary hypertension
The excess regurgitant blood entering in the LA may induce
acutely or in a chronic way a progressive rise in pulmonary
pressure. Pulmonary hypertension (PHT) is usually defined in
the literature as a resting sPAP >50 mmHg or an exercise sPAP
>60 mmHg. The prevalence of resting PHT in asymptomatic
patients with at least moderate MR ranges from 15 to 30%,15,16
while that of exercise PHT approximates 48%.15 In the MIDA
Registry, which included patients with flail MR, PHT was shown
to independently predict overall survival, post-operative survival
and heart failure.17 This echoes resemblance to another study on
severe organic MR, which also showed poorer post-operative
survival compared to patients with sPAP >50 mmHg.18 The
caveat in both these studies was that a considerable proportion
of patients, 35–36%, were in NYHA III–IV, which raises the
question of whether the data applies to asymptomatic patients in
our context. The presence of exercise PHT predicts symptom
onset and helps to identify patients that require close follow-ups.
In terms of hard clinical endpoints, exercise PHT was associated
with lower symptom-free survival and more post-operative
adverse cardiac events, such as AF, stroke, cardiac-related hos-
pitalization and death.15,19 The survival is worse when both
exercise PHT and right ventricular dysfunction (tricuspid annu-
lar plane systolic excursion <19 mm) coexist.16 In the ESC/
EACTA guidelines, exercise-induced PHT can also be consid-
ered as a trigger for intervention if the patient is of low risk and
there is high probability of durable repair, albeit with a low
recommendation class (IIb). Exercise PHT is, however, not
covered in the ACC/AHA guidelines.
Atrial fibrillation
AF is common in patients with degenerative MR. One study
on MR due to flail leaflets reported an AF incidence of
approximately 5% per year, amounting to 18% at 5-year and





Symptom and LVEF >30% I I
Asymptomatic and LVEF 30–60% I I
Asymptomatic and LVESD ≥40 mm – I
Asymptomatic and LVESD ≥45 mm I
Asymptomatic with flail leaflet and LVESD ≥40 mm,
with low surgical risk and high likelihood of repair
IIa IIa
Asymptomatic and new onset AF or sPAP ≥50 mmHg IIa IIa
MV repair reasonable in asymptomatic patients with
LVESD <40 mm and LVEF ≥60% when likelihood
of successful and durable repair without residual
MR is > 95% with and expected mortality rate
<1% when performed at Heart Valve Center of
Excellence
– IIa
Asymptomatic with left atrial dilatation (≥60 ml/m2)
or exercise sPAP ≥60 mmHg when there is a low
surgical risk and high likelihood of repair
IIb
Note. LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
diameter; AF, atrial fibrillation; sPAP, systolic pulmonary artery pressure.
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48% at 10-year follow up. AF is associated with a higher rate
of cardiac death and heart failure when patients are managed
conservatively.20 In patients who did receive surgical inter-
vention, 42% of the patients had already developed AF at the
time of surgery. The presence of AF before surgery is asso-
ciated with long-term mortality and post-operative LV
dysfunction.21,22 As such, patients with new onset of AF are
particularly well-suited for surgery as there is a chance that
sinus rhythm may be restored following surgery, before AF
begets more AF and the LA dilates permanently. The presence
of AF represents a class IIa indication for mitral valve surgery.
LA enlargement
The LA dilates in response to chronic volume and pressure
overload. An excessive increase in the LA size to an indexed
LA volume ≥60 ml/m2 is associated with increased mortality
and cardiac events in patients with primary MR.18 The
Figure 1. Examples of echocardiographic prognostic parameters in severe primary MR. (A) LVEF <60% or LV end systolic diameter ≥45 mm (2012 ESC/EACTA)/
≥40 mm (2014 ACC/AHA), Class I. (B) Pulmonary artery systolic pressure ≥50 mmHg at rest, Class IIa. (C) Left atrial volume index ≥60 ml/m2, Class IIb. (D) Exercise
pulmonary artery systolic pressure ≥60 mmHg, Class IIb. (E) Impaired LV global longitudinal strain (LS) at rest (<−20%). (F) Impaired LV contractile reserve at exercise
(<−2% increase in longitudinal strain, LS).
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predictors of LA enlargement are in turn, higher mitral regur-
gitant volume, AF, older age, female gender, higher LV end-
systolic volume and mass.23 LA enlargement carries a class IIb
recommendation for surgery in the ESC/EACTA guidelines if
the surgery is low risk and there is high probability of durable
repair. It is however, not covered in the ACC/AHA guidelines.
Emerging biomarkers and imaging techniques in the risk
stratification of MR (Table 2)
Brain natriuretic peptide
Increase in serum brain natriuretic peptide (BNP) level is
associated with poor outcomes in patients with primary MR.
In an earlier series of patients with various degrees of MR and
some being symptomatic, a BNP value ≥31 pg/mL was asso-
ciated with death and heart failure.24 In asymptomatic patients
with severe MR, a higher BNP cutoff value (≥105 pg/mL) has
been shown to identify patients with higher risk of heart failure,
LV dysfunction and death.25 Our group has also shown that in
asymptomatic degenerative MR patients, BNP release correlates
with increased LA volume and decreased LV longitudinal
function.26 BNP also has added prognostic value in the face
of a normal exercise LV systolic function. A rise in BNP
predicts the development of exercise PHT and LA enlargement
even when the exercise LVEF is normal.27 It has also been
suggested that BNP reflects primarily the hemodynamic con-
sequences of MR such as an increase in LV end-systolic volume
index rather than symptoms.24
Detection of fibrosis using MRI
One of the strongest suits of cardiac MRI at stratifying MR
patients lays on its ability to detect myocardial fibrosis.
Cardiac MRI enables detection of discrete fibrosis using late
gadolinium enhancement sequences and diffuse fibrosis using
novel techniques such as T1 mapping and extracellular
volume calculation. The presence of fibrosis, whether in the
form of late gadolinium enhancement or extracellular volume
expansion in primary MR, has been shown to predict adverse
LV remodeling and reduced LVEF. Studies have shown that
patients with late gadolinium enhancement on cardiac MRI
have higher LVESD.28,29 In addition, patients with higher
extracellular volume have reduced exercise capacity, higher
LVESD and lower LVEF.30 On a different note, the presence
of fibrosis in patients with MV prolapse and mild MR corre-
lates with ventricular arrhythmias and sudden cardiac death.31
Myocardial deformation and subclinical LV dysfunction
Myocardial deformation measured using 2D strain imaging is
useful at detecting subclinical LV dysfunction. In particular,
measurement of global longitudinal strain by speckle-tracking
technique has been shown to predict post-surgery LV function
and mortality. A global longitudinal strain below −18% to
−20.5% is associated with LV systolic dysfunction after
surgery,9,32–34 while a global longitudinal strain below −20%
predictors poorer event-free survival.35 Moreover, the absence
of contractile reserve, weaker changes in global longitudinal
strain (<−2%) revealed by exercise stress echocardiography,
also identifies patients with subclinical LV dysfunction at
higher risk of events and of post-operative decrease in LVEF.36
Early surgery versus watchful waiting in severe
asymptomatic PMR
One of the most revolutionary changes in the recent ACC/
AHA guidelines ought to be the new IIa recommendation for
MV repair in severe asymptomatic patients who have no
evidence of LV dysfunction, as long as curative surgery is
likely, i.e. likelihood of a successful and durable repair without
residual MR >95% with an expected mortality rate <1%,
performed at a Heart Valve Center of Excellence. Some won-
der if this is the conclusion to the early intervention versus
watchful waiting debate. For the proponents of watchful wait-
ing, the answer is a resounding no. In fact, the debate is still
far from over. Judging from the numbers of qualifiers that
needs to be fulfilled, it is no mean feat and might only be
applicable to a handful of bona fide “Centers of Excellence.”
Nevertheless, the recommendation is appropriate and timely,
in view of the mounting evidence of excellent outcomes in
dedicated MV centers. It represents an ideal that some centers
have achieved and the rest should all strive towards.
Early surgery strategy
Early or prophylactic surgery refers to MV surgery before the
onset of symptoms and the LV function is still preserved (EF
>60% or LVESD <40 mm). The proponents of early surgery
argue that surgery performed after LV dysfunction, AF or
PHT develop should be considered rescue surgery and like
all rescue operations, however noble the intention, not all can
be saved in time. One of the studies that is invariably men-
tioned to justify early surgery is the landmark paper by the
Mayo Clinic group, which showed that medically-managed
asymptomatic patients with severe MR, as defined by an
effective regurgitant orifice area (EROA) ≥40 mm2 had poor
long-term survival.37 The proponents of early surgery use this
to support intervention before it is too late, while the suppor-
ters of watchful waiting would beg to differ. In this elegant,
albeit historical study, the authors further divided the 198

































Biomarker Serum brain natriuretic
peptide
Note. LV, left ventricular; AF, atrial fibrillation; METs, metabolic equivalents; GLS,
global longitudinal strain.
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patients with severe MR into three strata according to EROA:
<20 mm2, 20–39 mm2 and ≥40 mm2. The proponents of
watchful waiting will be quick to point out that no doubt
the group with EROA ≥40 mm2 had poor outcome, but so did
the ERO 20–39 mm2 group, which had 34% mortality at 5-
year follow-up (versus 42% for ERO ≥40%). The lesson from
the study, in the words of the watchful waiters, is not to offer
surgery to all patients with poor outcome, but rather, to find
out why these patients had such poor outcome. Some of them
already had AF, PHT, and LVEF<60% at baseline. They would
have been offered surgery by today’s standard. Instead, they
were treated medically. Also, these patients did not have
dedicated regular follow-ups.
A more recent study supporting early surgery comes from
the MIDA registry, which showed that early surgery confers
superior long-term survival compared to medical management
in a propensity-matched cohort of patients.38 In this study,
limited to patients with flail MV, early surgery was defined by
operation within 3 months of diagnosis and it was compared
against an initial strategy of medical therapy. This study is not
without some caveats. It was a retrospective registry and the
reasons for or against surgery were unknown. In addition,
patients from the early surgery group were younger and more
often had PHT or other class II indications for surgery. In the
medical management arm, 19% of the patients had class II
indication for surgery (AF 10% and PHT12%) but did not
receive surgery. In other words, the early surgery group is not
exactly the asymptomatic patients with no surgical triggers that
we have been deliberating on. The same goes for the medical
therapy group, which is a strategy of only masterly inactivity
and not watchful waiting, which calls for surgical attention
once surgical triggers are met. One also needs to be cognizant
that this is a registry that spans decades and includes patients
since the year 1980. The diagnosis of MR then was very
different from what it is today. Doppler echocardiography for
example, was not widely available until the end of the 1980s. It
is therefore tricky to draw parallels between this study and the
current debate of early surgery versus watchful waiting.
Another study that is invariably cited to support early
surgery strategy is the series from south Korea, which showed
excellent outcome in the early surgery group compared to
conventional medical therapy.39 This study, however, raised
a few eyebrows among the opponents of early surgery. Firstly,
there was no surgical mortality whatsoever. Also, all patients
who were lost to follow-up were exclusively from the surgical
group and it is well-known that patients lost to follow-up are
usually associated with poor outcomes. The same group sub-
sequently expanded the study cohort and published another
study, also looking at early surgery versus conventional treat-
ment in asymptomatic severe MR. This time, there was no
difference in overall mortality. There was, however, a higher
rate of AF and fatal stroke associated with early surgery.
Again, there was no operative mortality in the surgical
group, a triumph in the eyes of naysayers, rather improbable.
In the subgroup analysis using an age cutoff of 50 years, the
reduction in cardiac events was only demonstrated in the
subgroup <50 years and not in those >50 years. The authors,
therefore, concluded that watchful waiting is preferred in
patients below 50 years and surgery should be considered in
selected patients above 50 years.40
Watchful waiting strategy: what is in a name
Watchful waiting is in fact a proactive approach. It involves a
structured surveillance system and readiness to intervene with
surgery when triggers emerge. The Heart Valve Clinic (HVC)
epitomizes this concept well. In the HVC, patients are being
followed-up regularly with timely electrocardiogram and
echocardiogram. They are also encouraged to report symp-
toms, if any. Once symptom develops or other surgical criteria
are met, prompt attention, ideally in the form of a multi-
disciplinary Heart Team is sought.41 An important argument
that supporters of early surgery often bring up is that early
surgery could benefit patients that default follow-up and con-
sequently surgical triggers were missed. It is true that prophy-
lactic surgery may have a role in parts of the world where
healthcare is not easily accessible and the attrition during
follow-up is high. However, when healthcare accessibility is
not an issue, the problem of lost to follow-up could be more
aptly addressed by having a dedicated clinician/nurse check-
ing on patients and reminding them to return for appoint-
ments at the HVC.
Watchful waiting strategy: critical considerations
There are a few additional considerations that one needs to
bear in mind when it comes to the execution of the watchful
waiting strategy (Table 3). First and foremost, one needs to
have no doubt about the severity of MR. Second, the func-
tional status of the patient, ideally obtained from stress testing
should be used to follow-up the patient longitudinally. Third,
one needs to recognize the degree to which other triggers are
inevitable and predictable. Finally, one ought to carefully
weigh the risk of surgery against the consequences of waiting
and individualize the decision according to the patient’s sur-
gical risk and the availability of surgical expertise.
Confirming the severity of MR. Having this diagnostic cer-
tainty is especially important when severe MR is the only
indication for surgery and other surgical triggers are not
met. In the wise words of Hippocrates, we should first do
no harm. The worst thing that could happen is sending a
patient who otherwise doesn’t need a surgery for one.
However, the humbling fact is that MR severity assessment
is complex. In practice, an integrated approach should be used
Table 3. Watchful waiting check list.
→ Symptoms and
functional capacity
→ Detailed anamnesis, Exercise stress test
→ Severity of MR → Imaging: TTE, TOE, MRI
→ Hemodynamic effects
of MR
→ LVEF, ESD, AF, LA dilatation, pulmonary
hypertension, GLS, BNP, etc.
→ Feasibility of MV repair → Valve morphology, Surgeon’s skill
→ Operative risk → EuroSCORE II, Society of Thoracic Surgeons
score
Note. MV, mitral valve; TTE, transthoracic echocardiography; TOE, transesopha-
geal echocardiography; MRI, magnetic resonance imaging; LVEF, left ventricu-
lar ejection fraction; ESD, end systolic diameter; AF, atrial fibrillation; LA, left
atrium; GLS, Global longitudinal strain; BNP, brain natriuretic peptide.
220 P. LANCELLOTTI ET AL.: MANAGEMENT OF ASYMPTOMATIC DEGENERATIVE MR STRUCTURAL HEART
and quantitative assessment should be performed.42
Meticulous attention should be given to the potential pitfalls
of each method of MR assessment. For example, in the con-
text of severe degenerative MR with MV prolapse, the regur-
gitant jet may only be tele- or meso-systolic. As such, the
EROA method may overestimate the severity of MR. Also,
when the echocardiographic window is limited or the inte-
grated approach yields conflicting information, cardiac MRI
could be considered as a complementary tool.43 However,
even in the hands of experienced readers, there could still be
substantial variations in MR severity grading. A recent study
comparing echocardiography and cardiac MRI assessment of
MR has shown that by echocardiographic criteria, 56% of the
patients had severe MR, while by MRI flow assessment, the
number of severe MR goes down to only 15%.44 MRI was also
shown to track ventricular response post-mitral surgery better
than echocardiography. Although it is hard to determine
which is the gold standard, this paper highlights the fact
that MR quantification is an evolving field in the current era
of multimodality imaging.
Functional and symptomatic status. Surgery is indicated
once a patient becomes symptomatic.45 Then, identifying
patients who are truly asymptomatic is fundamental.
Exercise stress testing is an objective way of confirming the
absence of symptoms and to define one’s true functional
capacity, compared against age-gender predicted standards.
Not infrequently, patients adapt their daily activities in order
to avoid symptoms. Studies have shown that up to 20% of
asymptomatic MR patients have reduced functional capacity
as represented by markedly reduced peak oxygen
consumption.23,46 Those patients are at higher risk of cardio-
vascular events, while delaying MV surgery by ≥1 year in
those with preserved exercise capacity did not adversely affect
outcomes.47 For those patients who achieved an age-gender
predicted METs of ≥85%, whether they underwent surgery or
were treated medically was inconsequential as there was no
difference between the two groups in terms of long-term
death, myocardial infarction, stroke, and heart failure.48
Are surgical triggers inevitable?. In the study by Rosenhek
and colleagues which followed asymptomatic severe MR
patients, 45% of patients developed surgical triggers, namely
LV dysfunction, LV dilatation, PHT or AF at 8-year.
Proponents of surgery may use this to argue that surgical
triggers are inevitable and to justify surgery before the onset
of triggers. The supporters of watchful waiting will, however,
focus on the other half, which is the 55% who are free of any
triggers at 8-year follow-up.49 The same analogy applies to the
MIDA study, which looked at long-term outcome of MR due
to flail leaflets on medical therapy. Heart failure developed in
50% and AF developed in 30% of the patients.50 Depending
on which camp one is from, one could either take the num-
bers at face value and arrive at the conclusion that complica-
tions are inevitable, hence arguing for early surgery, or look at
the other half, which is the 50% who did not have heart failure
and 70% who did not have AF, arguing against the fatalistic
viewpoint.
There a risk of sudden cardiac death if we defer surgery? In
the MIDA registry, the annual sudden cardiac death risk in no
or minimally symptomatic patients and EF >60% was <1%,50
a figure comparable to that of the normal population. This is
in line with another study, which showed that the risk of
sudden cardiac death in patients who did not reach surgical
triggers was <0.5% per year.40 Adding to the watchful waiting
argument is again the study by Rosenhek and colleagues,
which showed that watchful waiting conveyed no surgical
disadvantage and surgical outcomes in carefully followed-up
watchful waiters were excellent.49 In addition, there is no data
that suggest a difference in surgical or post-op outcomes in
terms of repair rates, LVEF and mortality between patients
who undergo early surgery and those who receive surgery
only when surgical criteria are met.
Are there potential risks associated mitral valve surgery?
Death, stroke and other morbidities. Surgery, as we know it,
is not without risks. In high-volume valve centers, the guide-
line target mortality <1% may be achievable. However, regis-
try data from the Society of Thoracic Surgeons, which reflects
the collective experience from a variety of centers showed
higher 30-day mortality rates, 1.2% for MV repair and 3.8%
if the MV is replaced. The incidence of ischemic or fatal
stroke after surgery for MR approximates 2%, which is not
negligible considering it is an elective surgery.51 For some
patients, the idea of a debilitating stroke may be tantamount
to, or sometimes, worse than sudden cardiac death. In terms
of overall major peri-operative events, which include opera-
tive mortality, renal failure, prolonged ventilation, stroke and
reoperation, the number amounts to 10% even in the high-
volume centers.52 A recent New York State-wide multicenter
study has shown that individual surgeons’ mitral valve case
volume has a significant impact on early- and long-term
patients’ outcomes after mitral valve surgery.53
Failure in mitral valve repair. Surgeons capable of successful
and durable MV repair are not universally available.53,54 On
average, a surgeon needs to perform at least 100 isolated
mitral cases per year in order to have a repair rate of 83%.
A total annual surgeon volume of <25 operations has been
reported to be associated not only with lower mitral valve
repair rates, but also with increased 1-year mortality and
mitral valve reoperation rates.53 The inconvenient truth is
that the median number of MV surgeries is five per surgeon
per year in the United States, which is associated with a repair
rate of 55%.55 In the Society of Thoracic Surgeons registry,
although the repair rate has improved steadily over the years,
the replacement rate for isolated primary MR is still over
30%56 and we are well aware that prosthesis at the mitral
position is associated with suboptimal outcomes. Also, there
is a risk of anticoagulation or infection at 1–2% per year.
Looking beyond the US, a study from the other side of the
ocean strikes a similar chord. The United Kingdom Adult
Cardiac Surgical Database Report sums it up well by compar-
ing the variability of MV repair rates in different hospitals to
that of the lottery system, in view of the wide range of repair
rates, from 20 to 90%.57 Last but not least, repair may not be a
permanent solution even in the best of hands. Take the
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surgical arm of EVEREST II trial for example. There is still a
possibility of 4+ MR at 2-year at surgical sites with high-
volume, skilled MV surgeons.58 In other studies, the risk of
recurrent MR was 2–3% per year,59,60 while the risk of re-do
operation was 1% per year even after a successful surgery.21
Take-home message
To recapitulate, early surgery and watchful waiting are both
viable options, substantiated by a plethora of evidence. The
key is to really carry out the spirit of what each strategy
embodies. As we have seen earlier, the majority of criti-
cisms on either strategy arise when there is deviation from
this principle. For instance, studies advocating early surgery
in asymptomatic patients might have inadvertently included
patients who are not truly asymptomatic due to a multitude
of reasons, one being the historical nature of these studies
and differences in the standard of care at the time of the
study. Another example of problems arising from not stay-
ing true to the spirit is in studies comparing medical
therapy to early surgery. Many a time, the medical therapy
arm only practices inactivity and not watchful waiting,
which requires vigilance and action readiness. We therefore
cannot stress enough the importance of clinical judgment at
interpreting these studies. Early surgery is not a sweeping
pass that is to be plastered across the board, a shield that
inferior outcomes can hide behind. It actually represents a
privilege that only those with the capability can exercise.
For those who advocate watchful waiting, it is not a secur-
ity blanket, which permits comfortable inaction. When the
surgical indications are met, it should be performed in a
timely manner. With regards to the future of risk stratifica-
tion in MR, our group believes that exercise stress testing
has a promising role.61 It has the ability to elicit symptoms,
enables objective assessment of functional capacity against
age-gender matched subjects, and provides a dynamic eva-
luation of myocardial structure and function. At the end of
the day, studies present numbers and figures that apply to a
population and not to an individual. As the treating physi-
cians, we should individualize care according to local prac-
tice settings, i.e. whether surgical and imaging expertise are
available, patient’s surgical risk profile and most impor-
tantly, patient’s preference. Time taken to understand
patient’s wishes and how they perceive risks will be proven
worthwhile. After all, it is the patient who is at the center
of the Heart Team and surgery should always be a joint
decision.
Conclusion
In conclusion, the indications and timing of surgery in
asymptomatic severe MR patients is both a science and an
art. The debate of early surgery versus watchful waiting in
the literature is analogous to Newton’s Third Law, in the
sense that with every argument, there is an equal and
opposite counter-argument. This debate seems unlikely
to resolve at least in the near future. In the words of
Pliny the Elder, in these matters the only certainty is
that nothing is certain. It is a matter that calls for sound
clinical judgement, humility of wisdom, and further
research.
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